September 2013 | Oncology & Biotech News

Epigenetic Variations in Prostate Tumors May Determine Choice Between Definitive Treatment and Active Surveillance

October 16, 2013

Prostate cancer is the most common cancer and second leading cause of cancer mortality in American men. Nevertheless, it is estimated that only 3% of the patients will die because of their cancer, while the majority will die of competing causes.

A Leader in Both Research and Practice

October 15, 2013

Few of ASCO's past presidents were faced with the multitude of challenges that arose during the presidency of Sandra M. Swain, MD, who is medical director of the Washington Cancer Institute at Medstar Washington Hospital Center and a professor of Medicine at Georgetown University, and is currently ASCO's immediate past president.

Verastem Targets Cancer Stem Cells

October 08, 2013

Cancer stem cells are an underlying cause of a tumor's ability to recur and metastasize even after initial treatment. Therefore, targeting those cancer stem cells could prove to be a valuable tool in the treatment of several different tumor types.

It's All in the "Genes"

September 23, 2013

I remember trying to explain to my son when he was in the fifth grade how the genetic code contained in all of our cells is translated, resulting in the various tissues we all possess for daily life

Merrimack's GI Cancer Agents Show Promise

September 20, 2013

Merrimack Pharmaceuticals is combining biology, computing, and engineering in order to gain a comprehensive understanding of the dynamics of different types of cancer and then use that information to develop new therapeutics.

New Data May Dispel Safety Concerns With 5-ARI Use in Prostate Cancer Prevention

September 19, 2013

The Prostate Cancer Prevention Trial, conducted from January 1997 to February 2003, demonstrated that the 5α-reductase inhibitor (5-ARI) finasteride reduced the risk of developing prostate cancer in men being regularly screened for the disease